Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “lung cancer”

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerActive Not Recruiting
NCT04514497Phase 1Updated Jul 31, 2026
Sponsor: National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma · Metastatic Malignant Solid Neoplasm · Metastatic Neuroendocrine Carcinoma · Metastatic Pancreatic Adenocarcinoma
United States
Adaptive Symptom Self-Management Immunotherapy StudyActive Not Recruiting
NCT05715255NAUpdated Jul 31, 2026
Sponsor: University of Arizona
Breast Cancer · Colon Cancer · Lung Cancer · Skin Cancer
United States
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Recruiting
NCT06667076Phase 2Updated Jul 31, 2026
Sponsor: Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
United States, Belgium, Finland, France, Germany +9 more
Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment RecommendationsRecruiting
NCT07739121N/AUpdated Jul 31, 2026
Sponsor: Assistance Publique - Hôpitaux de Paris
Breast Neoplasms · Lung Neoplasms · Urologic Neoplasms · Prostatic Neoplasms
France
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung CancerActive Not Recruiting
NCT04216316Phase 1, Phase 2Updated Jul 31, 2026
Sponsor: National Cancer Institute (NCI)
Lung Non-Small Cell Squamous Carcinoma · Stage IV Lung Cancer AJCC v8
United States
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerNot Yet Recruiting
NCT07739758Phase 3Updated Jul 31, 2026
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
SCLC, Extensive Stage
China
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or CarboplatinActive Not Recruiting
NCT02535312Phase 1, Phase 2Updated Jul 31, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm · Advanced Peritoneal Malignant Mesothelioma · Advanced Pleural Malignant Mesothelioma · Recurrent Peritoneal Malignant Mesothelioma
United States
Tarlatamab for SCLC Brain MetastasesRecruiting
NCT07402343Phase 2Updated Jul 31, 2026
Sponsor: Maastricht University Medical Center
Small Cell Lung Cancer · Brain Metastases, Adult
Netherlands
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active Not Recruiting
NCT04656652Phase 3Updated Jul 31, 2026
Sponsor: Daiichi Sankyo
Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +21 more
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive Not Recruiting
NCT04606771Phase 2Updated Jul 30, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Argentina, India, Taiwan, Thailand +1 more
Preliminary Evaluation of a Large Language Model-Based Tool for Complex Surgical Decision Support in Lung CancerCompleted
NCT07654036NAUpdated Jul 30, 2026
Sponsor: Peking University People's Hospital
Large Language Models · Lung Cancer (NSCLC)
China
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)Recruiting
NCT07252739Phase 2Updated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Chile, China, Finland, Greece +8 more
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Active Not Recruiting
NCT05973773Phase 3Updated Jul 30, 2026
Sponsor: Taiho Oncology, Inc.
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
United States, Belgium, Brazil, Bulgaria, Canada +18 more
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)Recruiting
NCT04165798N/AUpdated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +4 more
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerRecruiting
NCT05267626Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: Aulos Bioscience, Inc.
Advanced Solid Tumor · Metastatic Cancer · Cutaneous Melanoma · Non-Small Cell Lung Cancer
United States, Australia
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)Recruiting
NCT07492680Phase 2Updated Jul 30, 2026
Sponsor: Bristol-Myers Squibb
Solid Tumors
United States, Belgium, Canada, China, France +8 more
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruiting
NCT07285044Phase 2Updated Jul 30, 2026
Sponsor: Mayo Clinic
Amyloidosis · Basal Cell Carcinoma · Biliary Tract Carcinoma · Bladder Carcinoma
United States
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsRecruiting
NCT07094113Phase 1Updated Jul 30, 2026
Sponsor: Amgen
KRAS Altered Advanced or Metastatic Solid Tumors
United States, Australia, Belgium, Canada, China +9 more
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active Not Recruiting
NCT06710132Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Solid Tumors · Gastric Cancer · Non-Small Cell Lung Cancer (NSCLC) · Pancreatic Cancer
United States, Australia, Austria, China, France +5 more
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung CancerCompleted
NCT02718066Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: HUYABIO International, LLC.
Melanoma · Renal Cell Carcinoma · Non-Small Cell Lung Cancer
United States
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid MalignanciesRecruiting
NCT05039632Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm · Metastatic Malignant Neoplasm in the Liver · Metastatic Malignant Neoplasm in the Lung · Metastatic Malignant Solid Neoplasm
United States
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive Not Recruiting
NCT05891171Phase 1Updated Jul 30, 2026
Sponsor: Arcus Biosciences, Inc.
Advanced Cancer · Advanced Malignancies · Bladder Cancer · Cervical Cancer
United States, Australia, Taiwan
Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeActive Not Recruiting
NCT04340882Phase 2Updated Jul 30, 2026
Sponsor: Emory University
Metastatic Non-Small Lung Cell Cancer · Recurrent Non-Small Lung Cell Cancer · Stage IV Lung Cancer AJCC v8 · Stage IVA Lung Cancer AJCC v8
United States
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesRecruiting
NCT05327023Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: National Cancer Institute (NCI)
Hematologic Neoplasms
United States
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)Recruiting
NCT04165070Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
United States, Hungary, Israel, Italy, Poland +4 more

Previous page Next page